appetite

All articles tagged with “appetite”

Protocols

Semaglutide

The GLP-1 receptor agonist reshaping metabolic medicine, from weight loss to cardiovascular protection, liver repair, and beyond.

Semaglutide is a modified GLP-1 analogue with a ~1-week half-life, proven to reduce body weight by 10-17%, cut cardiovascular events by 20%, resolve fatty liver disease, and slow kidney decline. Its reach now extends into addiction, sleep apnea, and neuroinflammation.

semaglutideglp-1weight-lossozempicwegovy+4

PeptidesPeptide

PT-141 (Bremelanotide)

The first FDA-approved peptide that targets the brain's desire circuitry instead of the body's vascular hardware, opening a new front in sexual medicine, appetite regulation, and central neuromodulation.

PT-141 (bremelanotide) is a synthetic cyclic heptapeptide and centrally acting melanocortin receptor agonist FDA-approved for premenopausal female HSDD. It bypasses peripheral blood flow entirely, activating MC3R and MC4R in the hypothalamus to trigger dopamine and oxytocin release. Emerging data positions it as a post-GLP-1 weight rebound shield and a rescue therapy for PDE5 inhibitor non-responders in men.

pt-141

Protocols

PeptidesPeptide

Semaglutide

The GLP-1 receptor agonist reshaping metabolic medicine, from weight loss to cardiovascular protection, liver repair, and beyond.

Semaglutide is a modified GLP-1 analogue with a ~1-week half-life, proven to reduce body weight by 10-17%, cut cardiovascular events by 20%, resolve fatty liver disease, and slow kidney decline. Its reach now extends into addiction, sleep apnea, and neuroinflammation.

semaglutideglp-1weight-lossozempicwegovy+4

PeptidesPeptide

PT-141 (Bremelanotide)

The first FDA-approved peptide that targets the brain's desire circuitry instead of the body's vascular hardware, opening a new front in sexual medicine, appetite regulation, and central neuromodulation.

PT-141 (bremelanotide) is a synthetic cyclic heptapeptide and centrally acting melanocortin receptor agonist FDA-approved for premenopausal female HSDD. It bypasses peripheral blood flow entirely, activating MC3R and MC4R in the hypothalamus to trigger dopamine and oxytocin release. Emerging data positions it as a post-GLP-1 weight rebound shield and a rescue therapy for PDE5 inhibitor non-responders in men.

pt-141

bremelanotide

vyleesi

melanocortin

mc4r

+5